Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 7Carboplatin 5Cisplatin 4Drug Therapy 3Taxes 2Specimen Handling 2SS1(dsFv)PE38 2Polymerase Chain Reaction 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Hyperthermic Intraperitoneal Chemotherapy 2Gene Expression Profiling 2Fluorouracil 2Doxorubicin 2Cyclophosphamide 2130-nm albumin-bound paclitaxel 2tremelimumab 1tocilizumab 1tinostamustine 1sodium thiosulfate 1selinexor 1rucaparib 1olaparib 1motexafin lutetium 1liposomal doxorubicin 1fludarabine 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × eribulin × Thoracic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡